You are here

  • Home
  • Online First
  • Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases

Article Text

Article menu

other Versions

Download PDFPDF
Letter
Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases
  1. Hung Shih-Chang
  1. Nantou Hospital, Nantou, Taiwan
  1. Correspondence to Dr Hung Shih-Chang, Nantou Hospital, Nantou, Taiwan; shihchan{at}gmail.com

https://doi.org/10.1136/ejhpharm-2021-003018

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with interest the work by Shaw et al entitled ‘First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer’. The findings of this study are very inspiring for lung cancer treatment in Asian patients, especially those with brain metastases.1 I note that lorlatinib was found to be a very important treatment option in progression-free survival and overall survival rate. The hazard ratios (HRs) favoured lorlatinib over crizotinib across all subgroups of patients. In online supplemental figure S1, the HR …

    View Full Text

    Footnotes

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.